secwatch.observer — SEC 8-K summary
======================================

Issuer:     Jade Biosciences, Inc. (JBIO)
CIK:        0001798749
Form:       8-K
Filed at:   2026-04-22T23:59:59+00:00
Accession:  0001193125-26-168351
Event type: leadership
Sentiment:  neutral
Materiality: 0.20
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Andrew King promoted to President, R&D at Jade Biosciences
----------------------------------------------------------

- Andrew King previously CSO and Head of R&D appointed President Research & Development effective April 18 2026
- No changes to Dr Kings compensation were made in connection with the appointment
- King holds BVMS and Ph.D degrees and continues to lead R&D with expanded title

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526168351/0001193125-26-168351-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1798749/000119312526168351/d90643d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-168351

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer